Literature DB >> 27714768

Effects of S906T polymorphism on the severity of a novel borderline mutation I692M in Nav 1.4 cause periodic paralysis.

C Fan1, N Mao1,2, F Lehmann-Horn1, J Bürmann3, K Jurkat-Rott4.   

Abstract

Hyperkalemic periodic paralysis (HyperPP) is a dominantly inherited muscle disease caused by mutations in SCN4A gene encoding skeletal muscle voltage gated Nav 1.4 channels. We identified a novel Nav 1.4 mutation I692M in 14 families out of the 104 genetically identified HyperPP families in the Neuromuscular Centre Ulm and is therefore as frequent as I693T (13 families out of 14 HyperPP families) in Germany. Surprisingly, in 13 families, a known polymorphism S906T was also present. It was on the affected allele in at least 10 families compatible with a possible founder effect in central Europe. All affected members suffered from episodic weakness; myotonia was also common. Compared with I692M patients, I692M-S906T patients had longer weakness episodes, more affected muscles, CK elevation and presence of permanent weakness. Electrophysiological investigation showed that both mutants had incomplete slow inactivation and a hyperpolarizing shift of activation which contribute to membrane depolarization and weakness. Additionally, I692M-S906T significantly enhanced close-state fast inactivation compared with I692M alone, suggesting a higher proportion of inactivated I692M-S906T channels upon membrane depolarization which may facilitate the initiation of weakness episodes and therefore clinical manifestation. Our results suggest that polymorphism S906T has effects on the clinical phenotypic and electrophysiological severity of a novel borderline Nav 1.4 mutation I692M, making the borderline mutation fully penetrant.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Nav1.4; founder effect; hyperkalemic periodic paralysis; novel borderline mutation

Mesh:

Substances:

Year:  2016        PMID: 27714768     DOI: 10.1111/cge.12880

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  2 in total

1.  SCN4A as modifier gene in patients with myotonic dystrophy type 2.

Authors:  Anna Binda; Laura V Renna; Francesca Bosè; Elisa Brigonzi; Annalisa Botta; Rea Valaperta; Barbara Fossati; Ilaria Rivolta; Giovanni Meola; Rosanna Cardani
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

Review 2.  Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers?

Authors:  Antonino Lupica; Vincenzo Di Stefano; Andrea Gagliardo; Salvatore Iacono; Antonia Pignolo; Salvatore Ferlisi; Angelo Torrente; Sonia Pagano; Massimo Gangitano; Filippo Brighina
Journal:  Brain Sci       Date:  2021-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.